Overactive Bladder clinical trials at University of California Health
10 in progress, 8 open to eligible people
A Study of Oral vs Transdermal (through skin patch) Oxybutynin for Post-surgical Bladder Pain and Urgency in Children
open to eligible people ages 4-8
Bladder pain and urgency are common after bladder surgery. The objective is to determine if transdermal administration is superior to oral administration in alleviating pain and urgency.
at UC Davis
CAN-Stim Compared to SNS in Treatment of Urinary Urgency Incontinence With Wireless Neuromodulation Technology
open to eligible people ages 18 years and up
This is a prospective, randomized, controlled, multi-center, study in which 150 evaluable subjects will be randomized 1:1 to receive either a Protect CAN-Stim or SNS InterStim® system. Subjects from both groups will immediately start with therapy. The primary endpoint is a ≥ 50% reduction in number of incontinence episodes associated with urgency at the 3-month visit, with additional measurements assessed at 14 days, 1, 6, 9 and 12-months.
at UC Irvine
Evaluation of the TheraNova Neuromodulation System for the Treatment of Overactive Bladder Symptoms
open to eligible people ages 18 years and up
To evaluate the safety and effectiveness of the TheraNova Neuromodulation System in overactive bladder (OAB) patients. The primary safety endpoint will be device-related adverse events. The primary effectiveness endpoint will be urinary urge incontinence (UUI) responder rate at 12 weeks (a responder is defined as a subject who experiences at least a 50% reduction in the mean frequency of UUI events per day from baseline to 12 weeks as measured in the 3-day voiding diaries). Responder rate will be compared between subjects randomized to the active treatment vs. the sham treatment.
at UC Davis
Evaluation of the TheraNova Neuromodulation System to Provide Durable Relief of Overactive Bladder Symptoms
open to eligible people ages 18 years and up
To evaluate the safety and durability of the TheraNova Neuromodulation System in overactive bladder (OAB) patients.
at UC Davis
Intradetrusor Botulinum Toxin A: Are Less Injections Better?
open to eligible females ages 18 years and up
Patients with either overactive bladder (OAB) or urgency urinary incontinence (UUI) with be randomized (like a flip of a coin) to receive 100 units of bladder Botox® at either one injection site or ten injection sites. Efficacy and patient satisfaction will be measured by questionnaires.
at UC Irvine
Overactive Bladder Telemedicine Non-inferiority Trial
open to eligible people ages 18 years and up
In this study, the investigators aim to validate the telemedicine paradigm as a feasible alternative to traditional in-person clinic visits for the management of overactive bladder (OAB).
at UCLA
TEST-ON - Does iStim Reduce Urinary Urgency?
open to eligible females ages 18-120
Overactive bladder (OAB) is a chronic disorder with an overall prevalence in the adult population of over 10%, but that may exceed 40% in elderly groups. Most overactive bladder treatments are aimed at decreasing urgency incontinence episodes. The purpose of this study is to determine whether an at-home transvaginal electrical stimulation (TES) program works to alleviate symptoms of urgency in patients with urinary urgency and frequency without incontinence. This is a cross-over trial. Women >18 yo presenting with OAB-dry will be randomized to receive one of two TES at home programs for 4 weeks. After completion of the program, the participant's symptoms will be assessed with standardized patient questionnaires. There will then be a 3 week washout period followed by the second at-home TES program. At the completion of the second program, the participant's symptoms will be assessed with the same standardized questionnaires. The participants will be followed for 6 months following the completion of the TES program.
at UCLA
TReating Incontinence for Underlying Mental and Physical Health
open to eligible females ages 60 years and up
The TRIUMPH study is a randomized, double-blinded, 3-arm, parallel-group trial designed to compare the effects of anticholinergic bladder therapy versus a) beta-3-adrenergic agonist bladder therapy and b) no bladder pharmacotherapy on cognitive, urinary, and other aging-related functional outcomes in ambulatory older women with urgency-predominant urinary incontinence and either normal or mildly impaired cognitive function at baseline.
at UCSF
BlueWind RENOVA iStim™ System for the Treatment of OAB
Sorry, in progress, not accepting new patients
The OASIS study is prospective, interventional, multi-center study to evaluate the safety and efficacy of the BlueWind RENOVA iStim™ implantable tibial neuromodulation System for the treatment of patients diagnosed with overactive bladder.
at UC Irvine
InterStim Micro Post Market Clinical Follow-up Study
Sorry, in progress, not accepting new patients
Post-market clinical follow-up for continued assessment of safety and performance to confirm long-term outcomes of the InterStim Micro System for sacral neuromodulation.
at UCLA
Our lead scientists for Overactive Bladder research studies include Anne L Ackerman, MD, PhD Elaine Waetjen, MD Alison Huang, MD, MAS, MPhil Eric A Kurzrock, MD Felicia Lane, MD Victor W. Nitti, MD.
Last updated: